Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Zeeshan Shaikh, MD

Family Medicine Houston, TX Male

NPI: 1114210416

Total Payments

$16,652

2023 Payments

$19.14

Companies

Transactions

Medicare Patients

429

Medicare Billing

$50,185

Payment Breakdown by Category

Travel$11,878 (71.3%)

Research$3,182 (19.1%)

Food & Beverage$1,592 (9.6%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Travel and Lodging	$11,878	14	71.3%
Unspecified	$3,182	22	19.1%
Food and Beverage	$1,592	18	9.6%

Payments by Type

General

$13,470

32 transactions

Research

$3,182

22 transactions

Top Paying Companies

Company	Total	Records	Latest Year
Novo Nordisk AS	$13,735	20	$0 (2022)
Gilead Sciences, Inc.	$1,748	18	$0 (2019)
Kowa Research Institute, Inc.	$1,069	10	$0 (2017)
Genentech USA, Inc.	$51.11	3	$0 (2020)
Novo Nordisk Inc	$28.59	2	$0 (2017)
Lilly USA, LLC	$19.14	1	$0 (2023)

Payment History by Year

Year	Amount	Transactions	Top Company
2023	$19.14	1	Lilly USA, LLC ($19.14)
2022	$1,434	4	Novo Nordisk AS ($1,434)
2020	$51.11	3	Genentech USA, Inc. ($51.11)
2019	$11,919	26	Novo Nordisk AS ($10,171)
2017	$3,228	20	Novo Nordisk AS ($2,131)

All Payment Transactions

54 individual payment records from CMS Open Payments — Page 1 of 3

Date	Company	Product	Nature	Form	Amount	Type
06/08/2023	Lilly USA, LLC	TRULICITY (Drug), MOUNJARO	Food and Beverage	In-kind items and services	$19.14	General
Category: Diabetes
05/13/2022	Novo Nordisk AS	Ozempic (Drug)	—	In-kind items and services	$125.00	Research
Study: NN9535-4321 • Category: Diabetes
05/12/2022	Novo Nordisk AS	Ozempic (Drug)	—	In-kind items and services	$291.56	Research
Study: NN9535-4321 • Category: Diabetes
05/11/2022	Novo Nordisk AS	Ozempic (Drug)	—	In-kind items and services	$592.74	Research
Study: NN9535-4321 • Category: Diabetes
05/11/2022	Novo Nordisk AS	Ozempic (Drug)	—	In-kind items and services	$424.39	Research
Study: NN9535-4321 • Category: Diabetes
10/21/2020	Genentech USA, Inc.	Xofluza (Drug)	Food and Beverage	In-kind items and services	$23.23	General
Category: Virology & Specialty Care
03/02/2020	Genentech USA, Inc.	Xofluza (Drug)	Food and Beverage	In-kind items and services	$12.29	General
Category: Virology & Specialty Care
01/14/2020	Genentech USA, Inc.	Xofluza (Drug)	Food and Beverage	In-kind items and services	$15.59	General
Category: Virology & Specialty Care
09/14/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$58.24	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/14/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$15.74	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/13/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$66.77	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/13/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$47.90	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/13/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$47.90	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/13/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$41.39	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/13/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$18.31	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/13/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$17.23	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/13/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$10.88	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/12/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$108.06	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/12/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$54.49	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/12/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$40.00	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/12/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$30.00	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/12/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$23.65	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/12/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$15.16	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/11/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$132.32	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
09/10/2019	Gilead Sciences, Inc.	—	—	Cash or cash equivalent	$490.70	Research
Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease

1 2 3 »

Research Studies & Clinical Trials

Study Name	Company	Amount	Records
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease	Gilead Sciences, Inc.	$1,748	18
NN9535-4321	Novo Nordisk AS	$1,434	4

Medicare Billing by Year

Year	Procedures	Beneficiaries	Services	Submitted	Medicare Paid
2023	7	145	257	$43,918	$16,029
2022	5	99	178	$31,990	$13,092
2021	3	72	159	$23,310	$8,609
2020	5	113	259	$40,452	$12,454

Total Patients

429

Total Services

853

Medicare Billing

$50,185

Procedure Codes

All Medicare Procedures & Services

20 procedure records from CMS Medicare Utilization

HCPCS	Description	Setting	Year	Patients	Services	Charges	Medicare Paid	Ratio
99214	Established patient office or other outpatient visit, 30-39 minutes	Office	2023	30	88	$19,360	$7,255	37.5%
99204	New patient office or other outpatient visit, 45-59 minutes	Office	2023	44	44	$14,784	$4,768	32.3%
99213	Established patient office or other outpatient visit, 20-29 minutes	Office	2023	18	43	$6,450	$2,772	43.0%
87426	Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus	Office	2023	13	13	$1,040	$450.06	43.3%
87804	Detection test by immunoassay with direct visual observation for influenza virus	Office	2023	12	23	$690.00	$373.06	54.1%
96372	Injection of drug or substance under skin or into muscle	Office	2023	16	27	$1,404	$251.02	17.9%
36415	Insertion of needle into vein for collection of blood sample	Office	2023	12	19	$190.00	$159.60	84.0%
99214	Established patient office or other outpatient visit, 30-39 minutes	Office	2022	29	78	$17,140	$6,763	39.5%
99213	Established patient office or other outpatient visit, 20-29 minutes	Office	2022	22	46	$6,950	$3,260	46.9%
99204	New patient office or other outpatient visit, 45-59 minutes	Office	2022	20	20	$6,720	$2,506	37.3%
87426	Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus	Office	2022	12	12	$960.00	$499.16	52.0%
36415	Insertion of needle into vein for collection of blood sample	Office	2022	16	22	$220.00	$65.19	29.6%
99214	Established patient outpatient visit, total time 30-39 minutes	Office	2021	29	77	$16,940	$6,186	36.5%
99213	Established patient outpatient visit, total time 20-29 minutes	Office	2021	22	39	$5,850	$2,295	39.2%
36415	Insertion of needle into vein for collection of blood sample	Office	2021	21	43	$520.00	$129.00	24.8%
99214	Established patient office or other outpatient, visit typically 25 minutes	Office	2020	32	98	$21,560	$6,703	31.1%
99213	Established patient office or other outpatient visit, typically 15 minutes	Office	2020	26	75	$11,320	$4,074	36.0%
99204	New patient office or other outpatient visit, typically 45 minutes	Office	2020	17	17	$5,712	$1,348	23.6%
96372	Injection beneath the skin or into muscle for therapy, diagnosis, or prevention	Office	2020	13	15	$780.00	$168.20	21.6%
36415	Insertion of needle into vein for collection of blood sample	Office	2020	25	54	$1,080	$160.86	14.9%

About Dr. Zeeshan Shaikh, MD

Dr. Zeeshan Shaikh, MD is a Family Medicine healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2011. The National Provider Identifier (NPI) number assigned to this provider is 1114210416.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Zeeshan Shaikh, MD has received a total of $16,652 in payments from pharmaceutical and medical device companies, with $19.14 received in 2023. These payments were reported across 54 transactions from 6 companies. The most common payment nature is "Travel and Lodging" ($11,878).

As a Medicare-enrolled provider, Shaikh has provided services to 429 Medicare beneficiaries, totaling 853 services with total Medicare billing of $50,185. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Family Medicine
Other Specialties Family Medicine
Location Houston, TX
Active Since 05/18/2011
Last Updated 07/22/2013
Taxonomy Code 207Q00000X
Entity Type Individual
Practice Solo Practitioner
NPI Number 1114210416

Products in Payments

Ozempic (Drug) $10,654
Xofluza (Drug) $51.11
TRULICITY (Drug) $19.14
Xultophy 100/3.6 (Drug) $16.04
Victoza (Drug) $12.55

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.